Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Study of Auditory Perception After Progressive Exposure to Aversive Sounds in People With Misophonia

NCT06921187 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2025-06
Last updated
2025-04-10

Condition(s) studied

Misophonia

Investigational drug(s) / intervention(s)

Psychoacoustic testsemi-structured interviewsExposure to unpleasant sounds

Psychoacoustic test: Natural sounds will be presented at different decibels (dB), and the subject will be asked to rate the pleasantness/unpleasantness of the sound heard on a visual analogue scale, as well as the loudness (subjective intensity) of the sound heard.

semi-structured interviews: interview, designed under the supervision of a psychologist and using the methodology of micro-phenomenological interviews the aim of these interviews is to gain access to the participants' experiences, as they describe them in the first person, during misophonic episodes

Exposure to unpleasant sounds: Home exposure is a practice whereby participants voluntarily subject themselves to SMs in a controlled environment. Participants will be asked to complete two tasks: firstly, they will have to expose themselves to all 10 sounds at least twice a week; secondly, they will have to record the annoyance felt for each sound and the subjective loudness (loudness) of each SM using VAS.

Study summary

The primary objective of the project is to characterise and measure the auditory perception of subjects with misophonia compared with the auditory perception of control subjects.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: For all participants * Obtain oral consent from the participant after receiving information about the study, * Be 18 years or older on the day of inclusion, * Be fluent in French (spoken and written), * Have no known hearing loss, verified by pure tone audiometry. * Declare that they do not have tinnitus, * Declare that they do not have hyperacusis, verified by measuring discomfort thresholds. * Be affiliated to the social security or equivalent scheme. For participants with misophonia: \- Declare discomfort, reduced tolerance to specific sounds (mouth noises, throat clearing, breathing, etc.). Exclusion Criteria: * Bear the after-effects of an ear infection and/or have a history of an ENT disease that permanently affects hearing or balance (vestibular schwannoma, Ménière's disease, sudden or fluctuating deafness, congenital hypoacusis), * Be under guardianship, * deprived of liberty by judicial or administrative decision, or subject to legal protection.

Primary outcome measure(s)

  • score on a visual analogue scale from 0 (pleasant sound) to 10 (unpleasant sound) — 1 week after enrollment
    sounds will be presented at different decibels and the subject will be asked to rate the pleasantness/unpleasantness of the sound on a visual analogue scale
  • score on a visual analogue scale from 0 (very low intensity) to 10 (extremely intense) — 1 week after enrollment
    sounds will be presented at different decibels and the subject will be asked to rate the intensity of the sound on a visual analogue scale

Trial sites (2)

FacilityCityRegionStatus
Centre de Recherche en Psychologie et Neuroscience (CRPN) Marseille France
CEntre de Recherche et d'Innovation en Audiologie Humaine Paris France
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06921187 on ClinicalTrials.gov ↗ ← All trials in France